Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 4, 2003, Pages 1419-1422

  De la Campa, Adela G ^a   Ferrandiz, María José ^a,c   Tubau, Fe ^b   Pallarés, Román ^b   Manresa, Federico ^b   Liñares, Josefina ^b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Institute of Infection Immunity and Inflammation   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIUM ISOLATION; BRONCHIECTASIS; CASE REPORT; DRUG EFFECT; GENETIC ANALYSIS; HUMAN; INFECTION RISK; MALE; MULTIDRUG RESISTANCE; POINT MUTATION; PRIORITY JOURNAL; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE; TISSUE CHARACTERIZATION;

ANTI-INFECTIVE AGENTS; BRONCHIECTASIS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; HUMANS; MALE; MIDDLE AGED; MUTATION; STREPTOCOCCUS PNEUMONIAE;

EID: 0037379346     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.4.1419-1422.2003     Document Type: Article

References (35)

1. Alou, L., M. Ramirez, C. García-Rey, J. Prieto, and H. de Lencastre. 2001. Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones. Antimicrob. Agents Chemother. 45:2955-2957.
2. American Thoracic Society. 2001. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 163: 1730-1754.
3. Balas, D., E. Fernández-Moreira, and A. G. de la Campa. 1998. Molecular characterization of the gene encoding the DNA gyrase A subunit of Streptococcus pneumoniae. J. Bacteriol. 180:2854-2861.
4. Bartlett, J. G., S. F. Dowell, L. A. Mandell, T. L. File, Jr, D. L. Musher, and M. J. Fine. 2000. Guidelines from IDSA: practice guidelines for the management of adults with community-acquired pneumonia in adults. Clin. Infect. Dis. 31:347-382.
5. Bartlett, J. G., R. F. Breiman, L. Mandell, and T. M. File. 1998. Communityacquired pneumonia in adults: guidelines for management. Clin. Infect. Dis. 26:811-838.
6. Claverys, J.-P., M. Prudhomme, I. Martier-Barrière, and B. Martin. 2000. Adaptation to the environment: Streptococcus pneumoniae, a paradigm for recombination-mediated genetic plasticity? Mol. Microbiol. 35:251-259.
7. Chen, D. K., A. McGeer, J. C. de Azavedo, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233-239.
8. Davidson, R., R. Cavalcanti, J. L. Brunton, D. J. Bast, J. C. S. de Azevedo, P. Kibsey, C. Fleming, and D. E. Low. 2002. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 346:747-750.
9. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
10. Fernández-Moreira, E., D. Balas, I. González, and A. G. de la Campa. 2000. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase than DNA gyrase native proteins. Microb. Drug Res. 6:259-267.
11. González, I., M. Georgiou, F. Alcaide, D. Balas, J. Liñares, and A. G. de la Campa. 1998. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci. Antimicrob. Agents Chemother. 42:2792-2798.
12. Gootz, T. D., R. Zaniewski, S. Haskell, B. Schmieder, J. Tankovic, D. Girard, P. Courvalin, and R. J. Polzer. 1996. Activity of the new fluoroquinolone trovafloxacin (cp-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob. Agents Chemother. 40:2691-2697.
13. Hoffman, J., M. S. Cetron, M. M. Farley, W. S. Baughmam, R. R. Facklam, J. A. Elliot, K. A. Deaver, and R. F. Breiman. 1995. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N. Engl. J. Med. 333: 481-486.
14. Janoir, C., I. Podglajen, M. D. Kitzis, C. Poyart, and L. Gutmann. 1999. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis. J. Infect. Dis. 180:555-558.
15. Janoir, C., V. Zeller, M.-D. Kitzis, N. J. Moreau, and L. Gutmann. 1996. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40:2760-2764.
16. Liñares, J., A. G. de la Campa, and R. Pallarés. 1999. Fluoroquinolone resistance in Streptococcus pneumoniae. N. Engl. J. Med. 341:1546-1548.
17. McGee, L., L. McDougal, J. Zhou, B. G. Spratt, F. C. Tenover, R. George, R. Hakenbeck, W. Hryniewicz, J. C. Lefévre, A. Tomasz, and K. P. Klugman. 2001. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the Pneumococcal Molecular Epidemiology Network. J. Clin. Microbiol. 39:2565-2571.
18. Morrissey, I., and J. George. 1999. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins. Antimicrob. Agents Chemother. 43:2579-2585.
19. Muñoz, R., and A. G. de la Campa. 1996. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257.
20. NCCLS. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Publication M7-A5. NCCLS, Wayne, Pa.
21. NCCLS. 2002. Performance standards for antimicrobial susceptibility testing; twelfth informational supplement. Publication M100-S12. NCCLS, Wayne, Pa.
22. Pallarés, R., O. Capdevila, J. Liñares, I. Grau, H. Onaga, F. Tubau, M. H. Schulze, P. Hohl, and F. Gudiol. 2002. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am. J. Med. 113:120-126.
23. Pallarés, R., J. Liñares, M. Vadillo, C. Cabellos, F. Manresa, P. F. Viladrich, R. Martín, and F. Gudiol. 1995. Resistance to penicillin and cephalosporins and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333:474-480.
24. Pan, X. S., and L. M. Fisher. 1999. Streptococcus pnenmoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones. Antimicrob. Agents Chemother. 43:1129-1136.
25. Pan, X.-S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
26. Pan, X.-S., and L. M. Fisher. 1996. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J. Bacteriol. 178:4060-4069.
27. Pérez-Trallero, E., C. Fernández-Mazarrasa, C. Garcia-Rey, E. Bouza, L. Aguilar, J. García-de-Lomas, F. Baquero, and The Spanish Group for Respiratory Pathogens. 2001. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter study in Spain. Antimicrob. Agents Chemother, 45:3334-3340.
28. Pérez-Trallero, E., J. M. García-Arenzana, J. A. Jiménez, and A. Peris. 1990. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 9:905-906.
29. Perichon, B., J. Tankovic, and P. Courvalin. 1997. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:166-167.
30. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
31. Soares, S., K. G. Kristisson, J. M. Musser, and A. Tomasz. 1993. Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s. J. Infect. Dis. 168:158-163.
32. Tankovic, J., B. Perichon, J. Duval, and P. Courvalin. 1996. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40:2505-2510.
33. Tenover, F. C., R. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulse-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
34. Urban, C., N. Rahman, X. Zhao, N. Mariano, S. A. Segal-Maurer, K. Drlica, and J. J. Rahal. 2001. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J. Infect. Dis. 184:794-798.
35. Venditti, M., P. Baiocchi, C. Barandimarte, P. Serra, G. Gentile, C. Girmenia, and P. Martino. 1989. Antimicrobial susceptibilities of Streptococcus species that cause septicemia in neutropenic patients. Antimicrob. Agents Chemother. 33:580-582